Displaying drugs 7901 - 7906 of 7906 in total
Aviptadil
Experimental
Matched Iupac: … carboxypropanamido]propanamido]-3-methylbutanamido]-3-phenylpropanamido]-3-hydroxybutanamido]propanoic acid …
Vasoactive intestinal peptide
Investigational
Matched Iupac: … carboxypropanamido]propanamido]-3-methylbutanamido]-3-phenylpropanamido]-3-hydroxybutanamido]propanoic acid …
Taspoglutide
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no...
Investigational
Matched Iupac: … }methyl)carbamoyl]-4-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-2-methylpropanamido}butanoic acid …
Avexitide
Avexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia).
Investigational
Matched Iupac: … methylpentanamido]-3-hydroxypropanamido]hexanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]butanoic acid …
Brimapitide
Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Investigational
Matched Iupac: … carbamimidamido-1-oxopentan-2-yl]carbamoyl}-2-hydroxyethyl]carbamoyl}-3-carbamoylpropyl]carbamoyl}propanoic acid …
D-JNKI-1
A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the organ of Corti during times of oxidative stress.
Investigational
Matched Iupac: … carbamimidamido-1-oxopentan-2-yl]carbamoyl}-2-hydroxyethyl]carbamoyl}-3-carbamoylpropyl]carbamoyl}propanoic acid …
Displaying drugs 7901 - 7906 of 7906 in total